Pharma BD Deal Intelligence
Amgen paid $1.3-1.5B largely for a Bay Area beachhead and ~300 scientists — none of Tularik's five clinical drug candidates ever reached FDA approval, and Amgen wrote off $554M in acquired IPR&D almost immediately.
Full analysis, sources & comparables →"Amgen is excited about combining with Tularik, a high-science company that is focused on grievous illnesses and that shares our culture," said Kevin Sharer,…
"Amgen, the world's leading independent biotechnology company, has reached agreement to acquire the remaining 79% of fellow California, USA-based Tularik which…
Tularik, founded in 1991 by UC Berkeley Professor Robert Tjian, was acquired by Amgen for $1.3 billion in 2004; pipeline included T67, T607, T131 and…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Stock-for-stock; remaining 79% stake; small molecule R&D; closed Aug 13 2004
Amgen paid $1.3-1.5B largely for a Bay Area beachhead and ~300 scientists — none of Tularik's five clinical drug candidates ever reached FDA approval, and Amgen wrote off $554M in acquired IPR&D almost immediately.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Tularik Inc. (this deal) | 2004 | $1.3B | 33 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
← Browse all deals · How we score deals
More: 2004 deals · Amgen Inc. deals · Immunology deals